Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05564117 · ClinicalTrials.gov registry record · Phase 3
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 307
- Enrollment target
NCT05564117 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 307 participants.
The verdict
NCT05564117, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 307 participants
- Enrollment target
Study Summary
This study will look how well semaglutide tablets taken once daily helps people with body weight above the healthy range. Participants will either get semaglutide 25 milligram (mg) once daily or placebo once daily. This study will last for 72 weeks, which includes 1-week screening period, 64 weeks of treatment period and 7 weeks of follow up period.
Interventions
- DRUG Semaglutide
- DRUG Placebo semaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 307 participants |
| Start Date | 2022-10-11 |
| Est. Completion | 2024-05-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05564117
The ClinicalTrials.gov registry entry for NCT05564117 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 307 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Semaglutide is the first listed.
NCT05564117 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05564117 about?
NCT05564117 is a clinical study titled "Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range". This study will look how well semaglutide tablets taken once daily helps people with body weight above the healthy range. Participants will either get semaglutide 25 milligram (mg) once daily or placebo once daily. This study will last for 72 weeks, which includes 1-week screening period, 64 weeks o...
What is the current status of trial NCT05564117?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 307 participants. The study started on 2022-10-11. Estimated completion is 2024-05-07.
What interventions are being tested in trial NCT05564117?
The interventions under investigation include: Semaglutide (DRUG), Placebo semaglutide (DRUG).
Who is sponsoring clinical trial NCT05564117?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.